Cohort characteristics at time of progression on second-line TA for CLL
| Characteristic . | VEN → BTKi . | BTKi → VEN . | Whole cohort . |
|---|---|---|---|
| n = | 12 | 5 | 17 |
| Median age (range), y | 77 (52-92) | 74 (61-87) | 76 (52-92) |
| Median prior therapies* | 4.5 (2-8) | 4 (3-7) | 4 (2-8) |
| Fludarabine refractory (%) | 7 (58) | 2 (40) | 9 (53) |
| Prior PI3K inhibitor (%) | 0 (0) | 1/5 (20) | 1/17 (6) |
| RT prior to second-line TA (%) | 3 (25) | 0 (0) | 3 (18) |
| del(17p) and/or TP53 mutation (%) | 11/12 (92) | 4/5 (80) | 15/17 (88) |
| Complex karyotype, ≥3 abnormalities (%) | 8/8 (100) | 4/4 (100) | 12/12 (100) |
| IGHV unmutated (%) | 9/11 (82) | 2/2 (100) | 11/13 (85) |
| Concomitant rituximab with VEN (%) | 3 (25) | 0 (0) | 3 (18) |
| VEN: best response (%) | |||
| PD | 0 (0) | 0 (0) | 0 (0) |
| SD | 1 (8) | 2 (40) | 3 (18) |
| PR† | 7 (58) | 3 (60) | 10 (59) |
| CR MRD+ | 2 (17) | 0 (0) | 2 (12) |
| CR MRD− | 2 (17) | 0 (0) | 2 (12) |
| VEN: time to progression (range), mo | 24 (9-94) | 23 (6-29) | 24 (6-94) |
| BTKi: best response (%) | |||
| PD | 0 (0) | 0 (0) | 0 (0) |
| SD | 2 (17) | 1 (20) | 3 (18) |
| PR | 8 (67) | 4 (80) | 12 (71) |
| CR | 2 (17) | 0 (0) | 2 (12) |
| BTKi: Time to progression (range), mo | 25 (1-55) | 24 (4-42) | 25 (1-55) |
| Characteristic . | VEN → BTKi . | BTKi → VEN . | Whole cohort . |
|---|---|---|---|
| n = | 12 | 5 | 17 |
| Median age (range), y | 77 (52-92) | 74 (61-87) | 76 (52-92) |
| Median prior therapies* | 4.5 (2-8) | 4 (3-7) | 4 (2-8) |
| Fludarabine refractory (%) | 7 (58) | 2 (40) | 9 (53) |
| Prior PI3K inhibitor (%) | 0 (0) | 1/5 (20) | 1/17 (6) |
| RT prior to second-line TA (%) | 3 (25) | 0 (0) | 3 (18) |
| del(17p) and/or TP53 mutation (%) | 11/12 (92) | 4/5 (80) | 15/17 (88) |
| Complex karyotype, ≥3 abnormalities (%) | 8/8 (100) | 4/4 (100) | 12/12 (100) |
| IGHV unmutated (%) | 9/11 (82) | 2/2 (100) | 11/13 (85) |
| Concomitant rituximab with VEN (%) | 3 (25) | 0 (0) | 3 (18) |
| VEN: best response (%) | |||
| PD | 0 (0) | 0 (0) | 0 (0) |
| SD | 1 (8) | 2 (40) | 3 (18) |
| PR† | 7 (58) | 3 (60) | 10 (59) |
| CR MRD+ | 2 (17) | 0 (0) | 2 (12) |
| CR MRD− | 2 (17) | 0 (0) | 2 (12) |
| VEN: time to progression (range), mo | 24 (9-94) | 23 (6-29) | 24 (6-94) |
| BTKi: best response (%) | |||
| PD | 0 (0) | 0 (0) | 0 (0) |
| SD | 2 (17) | 1 (20) | 3 (18) |
| PR | 8 (67) | 4 (80) | 12 (71) |
| CR | 2 (17) | 0 (0) | 2 (12) |
| BTKi: Time to progression (range), mo | 25 (1-55) | 24 (4-42) | 25 (1-55) |
BTKi, Bruton tyrosine kinase inhibitor; CR, complete remission; IGHV, immunoglobulin heavy chain variable region; MRD, measurable residual disease; PD, progressive disease; PR, partial remission; SD, stable disease; VEN, venetoclax.
Refers to lines of therapy prior to initiation of the second-line TA.
No patients with partial remission in this cohort achieved undetectable measurable residual disease.